ERBB2 and breast cancer: Using a 10-miRNA classifier derived from breast cancer patient tissue biopsy, the recurrence of hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-breast cancer can be accurately predicted [138].